Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Assets: 2015-2024

Historic Non-Current Assets for Cartesian Therapeutics (RNAC) over the last 10 years, with Dec 2024 value amounting to $218.4 million.

  • Cartesian Therapeutics' Non-Current Assets fell 0.34% to $225.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.4 million, marking a year-over-year decrease of 0.34%. This contributed to the annual value of $218.4 million for FY2024, which is 1.90% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Non-Current Assets stood at $218.4 million for FY2024, which was up 1.90% from $214.3 million recorded in FY2023.
  • Over the past 5 years, Cartesian Therapeutics' Non-Current Assets peaked at $218.4 million during FY2024, and registered a low of $14.1 million during FY2020.
  • For the 3-year period, Cartesian Therapeutics' Non-Current Assets averaged around $150.2 million, with its median value being $214.3 million (2023).
  • Data for Cartesian Therapeutics' Non-Current Assets shows a peak YoY skyrocketed of 1,107.58% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Non-Current Assets stood at $14.1 million in 2020, then climbed by 9.57% to $15.4 million in 2021, then rose by 14.95% to $17.7 million in 2022, then skyrocketed by 1,107.58% to $214.3 million in 2023, then rose by 1.90% to $218.4 million in 2024.